Schedule

Friday, April 30, 2021
Noon – 1:00 p.m. ET
  •  Supported by Axsome Therapeutics Inc.
  •  [Product Theater 1] New Pathways in Depression: Potential to Improve Clinical Outcomes
  •  Roger S. McIntyre MD, FRCP
    Professor of Psychiatry and Pharmacology, University of Toronto, Head of the Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Canada
1:00 – 2:00 p.m. ET
  •  Supported by Sunovion Pharmaceuticals Inc.
  •  [Product Theater 2] Managing Patient Challenges with Functioning and Quality of Life in the Treatment of Bipolar Depression
  •  Gustavo Alva, M.D., DFAPA
    Assistant Professor, Department of Psychiatry and Neuroscience, University of California, Riverside, Medical Director, ATP Clinical Research, Costa Mesa, Calif., Consultant of Sunovion Pharmaceuticals Inc.
  •  Gregory W. Mattingly, M.D.
    Associate Clinical Professor, Washington University School of Medicine, President, Midwest Research Group, Board of Directors, American Professional Society for ADHD and Related Disorders, St. Charles, Mo., Consultant of Sunovion Pharmaceuticals Inc.
2:00 – 3:00 p.m. ET
  •  Supported by Neurocrine Biosciences, Inc.
  •  [Product Theater 3] Trending Topic: Update on Tardive Dyskinesia Screening and Treatment Guidelines
  •  Andrew J. Cutler, M.D.
    Chief Medical Officer, Neuroscience Education Institute, Carlsbad, Calif., Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, N.Y.
3:00 – 4:00 p.m. ET
  •  Supported by Sage and Biogen
  •  [Product Theater 4] Patient and Physician Perspectives on Major Depressive Disorder (MDD) and the Impact of COVID-19 on Mental Health
  •  Andrew Cutler, M.D.
  •  Roger McIntyre, M.D., FRCPC
  •  Dan Gillison
Saturday, May 1, 2021
11:10 – 11:30 a.m. ET
  •  Supported by Teva Pharmaceuticals Inc.
  •  [Huddle Session 1] Migraine and psychiatry: Where do they fit together?
  •  Steven M. Baskin, M.D.
1:00 – 2:00 p.m. ET
  •  Supported by AbbVie Inc.
  •  [Product Theater 5] The Management of Bipolar I Disorder
  •  Gustavo Alva, M.D., DFAPA
    ATP Clinical Research University of California, Riverside
1:00 – 2:00 p.m. ET
  •  Supported by Acadia Pharmaceuticals Inc.
  •  [Product Theater 6] Spotlight on Serotonin: Serotonin Dysfunction in Parkinson’s Disease and Psychosis
  •  Stephen M. Stahl, M.D., Ph.D., D.Sc. (Hon.)
3:40 – 4:00 p.m. ET
  •  Supported by Teva Medical (Movement Disorders)
  •  [Huddle Session 2] Tardive dyskinesia in clinical practice: Real or imagined?
  •  Craig Chepke, M.D.
Sunday, May 2, 2021
11:10 – 11:30 a.m. ET
  •  Supported by Teva Pharmaceuticals Inc.
  •  [Huddle Session 3] The Burden of Migraine in Patients With Comorbid Psychiatric Diseases
  •  Trupti B. Gokani, M.D.
1:00 – 2:00 p.m. ET
  •  Supported by Intra-Cellular Therapies
  •  [Product Theater 7] Use of Telepsychiatry to Manage Schizophrenia in Adults and Clinical Evidence Supporting a Treatment Option
  •  Andrew J. Cutler, M.D.
    Clinical Associate Professor, Chief Medical Officer, Neuroscience Education Institute, Carlsbad, Calif., Clinical Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, N.Y.
1:00 – 2:00 p.m. ET
  •  Supported by Otsuka America Pharmaceutical, Inc. and Lundbeck
  •  [Product Theater 8] Considerations on Mental Health During Uncertain Times, Followed by an Adjunctive Option for Adults with Major Depressive Disorder (MDD) Experiencing Partial Response on an Antidepressant
  •  Vladimir Maletic, M.D., M.S.
    Clinical Professor of Psychiatry and Behavioral Science, University of South Carolina School of Medicine, Greenville, S.C.
3:40 – 4:00 p.m. ET
  •  Supported by McLean Hospital
  •  [Huddle Session 4] Who Doesn’t Have a Personality Disorder?
  •  Lois Choi-Kain M.D.
Monday, May 3, 2021
11:10 – 11:30 a.m. ET
  •  Supported by Teva Pharmaceuticals Inc.
  •  [Huddle Session 5] Migraine and Psychiatric Disorders: Multidisciplinary Management for Quality Care
  •  Trupti B. Gokani, M.D.
  •  Lex Denysenko, M.D.
1:00 – 2:00 p.m. ET
  •  Supported by Janssen Pharmaceuticals, Inc.
  •  [Product Theater 9] SPRAVATO® and the Management of Two Subsets of Challenging to Treat Major Depressive Disorder (MDD) in Adults
  •  Rachel Dalthorp, M.D., Balance Women’s Health
  •  Rakesh Jain, M.D., Oyster Creek Associates, Pa.
1:00 – 2:00 p.m. ET
  • Supported by Eisai Inc.
  •  [Product Theater 10] Learning About a Treatment Option for Insomnia
  •  Gregory Mattingly, M.D.
3:40 – 4:00 p.m. ET
  •  Supported by Teva Medical (Movement Disorders)
  •  [Huddle Session 6] Do the APA Practice Guidelines discourage treatment of mild tardive dyskinesia?
  •  Craig Chepke, M.D.

View More: American Psychiatric Association 2021

Author